person · Reporting owner

Low Philip S

Disclosed activity across 2 companies

Tapewire entity: 127018
SEC CIK: 0001509669

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Quince Therapeutics, Inc.CRTX · Entity 7403	Director	May 19, 2022	May 23, 2022

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Quince Therapeutics, Inc.

Report date May 19, 2022 · Filed May 23, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	455,309	Reported balance After 2022-05-19 transaction · row 1 1 source row Row 1 · 2022-05-19 · Grant · Acquired 455,309 · Balance 455,309 F1: On March 19, 2022, the Issuer completed acquisition (the "Merger") of Novosteo Inc. ("Novosteo"), pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of May 9, 2022, (the "Merger Agreement"), by and among the Issuer, Quince Merger Sub I, Inc., a wholly owned subsidiary of the Issuer, Quince Merger Sub II, LLC, a wholly owned subsidiary of the Issuer, Novosteo, and Fortis Advisors LLC, solely in its capacity as the securityholders' representative. Pursuant to the terms of the Merger Agreement, at the closing of the Merger, the shares held by the Reporting Person in Novosteo were automatically cancelled and converted into the right to receive shares of common stock of the Issuer.
Common StockSEC Table I · non-derivative	IndirectBy Philip S. Low Revocable Trust	63,974	Reported balance After 2022-05-19 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2022-05-19 · Grant · Acquired 63,974 · Balance 63,974 F1: On March 19, 2022, the Issuer completed acquisition (the "Merger") of Novosteo Inc. ("Novosteo"), pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of May 9, 2022, (the "Merger Agreement"), by and among the Issuer, Quince Merger Sub I, Inc., a wholly owned subsidiary of the Issuer, Quince Merger Sub II, LLC, a wholly owned subsidiary of the Issuer, Novosteo, and Fortis Advisors LLC, solely in its capacity as the securityholders' representative. Pursuant to the terms of the Merger Agreement, at the closing of the Merger, the shares held by the Reporting Person in Novosteo were automatically cancelled and converted into the right to receive shares of common stock of the Issuer.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.30 · Expires 2032-05-18	Direct	22,058	Reported balance After 2022-05-19 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2022-05-19 · Grant · Acquired 22,058 · Balance 22,058 F2: The shares subject to the option shall vest in equal annual installments over the three-year period following the grant date of May 19, 2022.

Filing footnotes · ownership attribution and instrument terms

F1: On March 19, 2022, the Issuer completed acquisition (the "Merger") of Novosteo Inc. ("Novosteo"), pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of May 9, 2022, (the "Merger Agreement"), by and among the Issuer, Quince Merger Sub I, Inc., a wholly owned subsidiary of the Issuer, Quince Merger Sub II, LLC, a wholly owned subsidiary of the Issuer, Novosteo, and Fortis Advisors LLC, solely in its capacity as the securityholders' representative. Pursuant to the terms of the Merger Agreement, at the closing of the Merger, the shares held by the Reporting Person in Novosteo were automatically cancelled and converted into the right to receive shares of common stock of the Issuer.

F2: The shares subject to the option shall vest in equal annual installments over the three-year period following the grant date of May 19, 2022.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

ENDOCYTE INC

Report date December 21, 2018 · Filed December 21, 2018

Section 16 reporting ended · disclosed 2018-12-21. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2018-12-21 transaction · row 1 Sequence does not reconcile; account continuity is unresolved. 1 source row Row 1 · 2018-12-21 · Disposition to issuer · Disposed 349,944 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 17, 2018 (the "Merger Agreement"), by and among Endocyte, Inc. (the "Company"), Novartis AG ("Novartis") and Edinburgh Merger Corporation, a wholly owned subsidiary of Novartis ("Merger Sub"), at the effective time (the "Effective Time") of the merger of Merger Sub with and into the Company, which Effective Time occurred on December 21, 2018, each share of Company common stock was converted into the right to receive an amount in cash equal to $24.00, without interest and less any applicable withholding taxes.
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2018-12-21 transaction · row 3 Sequence does not reconcile; account continuity is unresolved. 1 source row Row 3 · 2018-12-21 · Disposition to issuer · Disposed 4,375 · Balance 0 F2: This restricted stock unit ("RSU") award, which originally consisted of 8,750 RSUs and of which 4,375 RSUs had vested and been settled as of immediately prior to the Effective Time, provided for vesting and settlement 1/4 annually over a period of 4 years beginning on February 4, 2017 in the form of one share of Company common stock for each RSU. Pursuant to the Merger Agreement, at the Effective Time, each RSU outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to $24.00, multiplied by the number of shares of Company common stock subject to such RSU, less any applicable withholding taxes.
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2018-12-21 transaction · row 4 Sequence does not reconcile; account continuity is unresolved. 1 source row Row 4 · 2018-12-21 · Disposition to issuer · Disposed 13,125 · Balance 0 F3: This RSU award, which originally consisted of 17,500 RSUs and of which 4,375 RSUs had vested and been settled as of immediately prior to the Effective Time, provided for vesting and settlement 1/4 annually over a period of 4 years beginning on February 2, 2018 in the form of one share of Company common stock for each RSU. Pursuant to the Merger Agreement, at the Effective Time, each RSU outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to $24.00, multiplied by the number of shares of Company common stock subject to such RSU, less any applicable withholding taxes.
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2018-12-21 transaction · row 5 Sequence does not reconcile; account continuity is unresolved. 1 source row Row 5 · 2018-12-21 · Disposition to issuer · Disposed 20,000 · Balance 0 F4: This RSU award, which originally consisted of 40,000 RSUs and of which 20,000 RSUs had vested and been settled as of immediately prior to the Effective Time, provided for vesting and settlement 1/2 annually over a period of 2 years beginning on October 4, 2018 in the form of one share of Company common stock for each RSU. Pursuant to the Merger Agreement, at the Effective Time, each RSU outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to $24.00, multiplied by the number of shares of Company common stock subject to such RSU, less any applicable withholding taxes.
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2018-12-21 transaction · row 6 Sequence does not reconcile; account continuity is unresolved. 1 source row Row 6 · 2018-12-21 · Disposition to issuer · Disposed 22,500 · Balance 0 F5: This RSU award provided for vesting and settlement 1/4 annually over a period of 4 years beginning on February 8, 2019 in the form of one share of Company common stock for each RSU. Pursuant to the Merger Agreement, at the Effective Time, each RSU outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to $24.00, multiplied by the number of shares of Company common stock subject to such RSU, less any applicable withholding taxes.
Common StockSEC Table I · non-derivative	IndirectBy Spouse Trust	Reported balance After 2018-12-21 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2018-12-21 · Disposition to issuer · Disposed 132,473 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 17, 2018 (the "Merger Agreement"), by and among Endocyte, Inc. (the "Company"), Novartis AG ("Novartis") and Edinburgh Merger Corporation, a wholly owned subsidiary of Novartis ("Merger Sub"), at the effective time (the "Effective Time") of the merger of Merger Sub with and into the Company, which Effective Time occurred on December 21, 2018, each share of Company common stock was converted into the right to receive an amount in cash equal to $24.00, without interest and less any applicable withholding taxes.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.82 · Expires 2020-02-11	Direct	Reported balance After 2018-12-21 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2018-12-21 · Disposition to issuer · Disposed 13,570 · Balance 0 F6: This Company stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.05 · Expires 2021-04-14	Direct	Reported balance After 2018-12-21 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2018-12-21 · Disposition to issuer · Disposed 8,560 · Balance 0 F6: This Company stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.80 · Expires 2021-05-26	Direct	Reported balance After 2018-12-21 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2018-12-21 · Disposition to issuer · Disposed 17,950 · Balance 0 F6: This Company stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.55 · Expires 2022-02-28	Direct	Reported balance After 2018-12-21 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2018-12-21 · Disposition to issuer · Disposed 59,996 · Balance 0 F6: This Company stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.86 · Expires 2023-02-19	Direct	Reported balance After 2018-12-21 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2018-12-21 · Disposition to issuer · Disposed 56,918 · Balance 0 F6: This Company stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.11 · Expires 2024-02-06	Direct	Reported balance After 2018-12-21 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2018-12-21 · Disposition to issuer · Disposed 36,000 · Balance 0 F6: This Company stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.10 · Expires 2025-02-04	Direct	Reported balance After 2018-12-21 transaction · row 13 Instrument identity requires review; Table II rows are not merged. 1 source row Row 13 · 2018-12-21 · Disposition to issuer · Disposed 52,498 · Balance 0 F6: This Company stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.18 · Expires 2026-02-04	Direct	Reported balance After 2018-12-21 transaction · row 14 Instrument identity requires review; Table II rows are not merged. 1 source row Row 14 · 2018-12-21 · Disposition to issuer · Disposed 52,498 · Balance 0 F7: This Company stock option was scheduled to vest 1/4 annually over a period of 4 years beginning on February 4, 2017. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.16 · Expires 2027-02-02	Direct	Reported balance After 2018-12-21 transaction · row 15 Instrument identity requires review; Table II rows are not merged. 1 source row Row 15 · 2018-12-21 · Disposition to issuer · Disposed 35,000 · Balance 0 F8: This Company stock option was scheduled to vest 1/4 annually over a period of 4 years beginning on February 2, 2018. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.01 · Expires 2028-02-08	Direct	Reported balance After 2018-12-21 transaction · row 16 Instrument identity requires review; Table II rows are not merged. 1 source row Row 16 · 2018-12-21 · Disposition to issuer · Disposed 45,000 · Balance 0 F9: This Company stock option was scheduled to vest 1/4 annually over a period of 4 years beginning on February 8, 2019. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger, dated as of October 17, 2018 (the "Merger Agreement"), by and among Endocyte, Inc. (the "Company"), Novartis AG ("Novartis") and Edinburgh Merger Corporation, a wholly owned subsidiary of Novartis ("Merger Sub"), at the effective time (the "Effective Time") of the merger of Merger Sub with and into the Company, which Effective Time occurred on December 21, 2018, each share of Company common stock was converted into the right to receive an amount in cash equal to $24.00, without interest and less any applicable withholding taxes.

F2: This restricted stock unit ("RSU") award, which originally consisted of 8,750 RSUs and of which 4,375 RSUs had vested and been settled as of immediately prior to the Effective Time, provided for vesting and settlement 1/4 annually over a period of 4 years beginning on February 4, 2017 in the form of one share of Company common stock for each RSU. Pursuant to the Merger Agreement, at the Effective Time, each RSU outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to $24.00, multiplied by the number of shares of Company common stock subject to such RSU, less any applicable withholding taxes.

F3: This RSU award, which originally consisted of 17,500 RSUs and of which 4,375 RSUs had vested and been settled as of immediately prior to the Effective Time, provided for vesting and settlement 1/4 annually over a period of 4 years beginning on February 2, 2018 in the form of one share of Company common stock for each RSU. Pursuant to the Merger Agreement, at the Effective Time, each RSU outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to $24.00, multiplied by the number of shares of Company common stock subject to such RSU, less any applicable withholding taxes.

F4: This RSU award, which originally consisted of 40,000 RSUs and of which 20,000 RSUs had vested and been settled as of immediately prior to the Effective Time, provided for vesting and settlement 1/2 annually over a period of 2 years beginning on October 4, 2018 in the form of one share of Company common stock for each RSU. Pursuant to the Merger Agreement, at the Effective Time, each RSU outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to $24.00, multiplied by the number of shares of Company common stock subject to such RSU, less any applicable withholding taxes.

F5: This RSU award provided for vesting and settlement 1/4 annually over a period of 4 years beginning on February 8, 2019 in the form of one share of Company common stock for each RSU. Pursuant to the Merger Agreement, at the Effective Time, each RSU outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to $24.00, multiplied by the number of shares of Company common stock subject to such RSU, less any applicable withholding taxes.

F6: This Company stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes.

F7: This Company stock option was scheduled to vest 1/4 annually over a period of 4 years beginning on February 4, 2017. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes.

F8: This Company stock option was scheduled to vest 1/4 annually over a period of 4 years beginning on February 2, 2018. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes.

F9: This Company stock option was scheduled to vest 1/4 annually over a period of 4 years beginning on February 8, 2019. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
May 19, 2022 Filed May 23, 2022 20:17 UTC	Quince Therapeutics, Inc. CRTX · Entity 7403	GrantStock Option (right to buy) · Derivative	22,058	$0.00 Strike: $3.30	$0.00	Disclosure SEC source: 0001209191-22-031503 · doc4.xml · derivative · entry 3 Low Philip S · CIK 0001509669 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,058 Underlying: Common Stock · 22,058 shares Expires 2032-05-18 F2 · derivative.exercise_date: The shares subject to the option shall vest in equal annual installments over the three-year period following the grant date of May 19, 2022. Read SEC document
May 19, 2022 Filed May 23, 2022 20:17 UTC	Quince Therapeutics, Inc. CRTX · Entity 7403	GrantCommon Stock	63,974	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-22-031503 · doc4.xml · nonDerivative · entry 2 Low Philip S · CIK 0001509669 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Philip S. Low Revocable Trust Disclosed balance after: 63,974 F1 · price: On March 19, 2022, the Issuer completed acquisition (the "Merger") of Novosteo Inc. ("Novosteo"), pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of May 9, 2022, (the "Merger Agreement"), by and among the Issuer, Quince Merger Sub I, Inc., a wholly owned subsidiary of the Issuer, Quince Merger Sub II, LLC, a wholly owned subsidiary of the Issuer, Novosteo, and Fortis Advisors LLC, solely in its capacity as the securityholders' representative. Pursuant to the terms of the Merger Agreement, at the closing of the Merger, the shares held by the Reporting Person in Novosteo were automatically cancelled and converted into the right to receive shares of common stock of the Issuer. Read SEC document
May 19, 2022 Filed May 23, 2022 20:17 UTC	Quince Therapeutics, Inc. CRTX · Entity 7403	GrantCommon Stock	455,309	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-22-031503 · doc4.xml · nonDerivative · entry 1 Low Philip S · CIK 0001509669 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 455,309 F1 · price: On March 19, 2022, the Issuer completed acquisition (the "Merger") of Novosteo Inc. ("Novosteo"), pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of May 9, 2022, (the "Merger Agreement"), by and among the Issuer, Quince Merger Sub I, Inc., a wholly owned subsidiary of the Issuer, Quince Merger Sub II, LLC, a wholly owned subsidiary of the Issuer, Novosteo, and Fortis Advisors LLC, solely in its capacity as the securityholders' representative. Pursuant to the terms of the Merger Agreement, at the closing of the Merger, the shares held by the Reporting Person in Novosteo were automatically cancelled and converted into the right to receive shares of common stock of the Issuer. Read SEC document
December 21, 2018 Filed Dec 21, 2018 12:47 UTC	ENDOCYTE INC ECYT · Entity 161591	Disposition to issuerStock Option (right to buy) · Derivative	45,000	$20.99 Strike: $3.01	$944,550.00	Disclosure SEC source: 0001104659-18-074339 · a4.xml · derivative · entry 16 Low Philip S · CIK 0001509669 · Director · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 45,000 shares Expires 2028-02-08 F9 · price: This Company stock option was scheduled to vest 1/4 annually over a period of 4 years beginning on February 8, 2019. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes. F9 · derivative.exercise_date: This Company stock option was scheduled to vest 1/4 annually over a period of 4 years beginning on February 8, 2019. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes. Read SEC document
December 21, 2018 Filed Dec 21, 2018 12:47 UTC	ENDOCYTE INC ECYT · Entity 161591	Disposition to issuerStock Option (right to buy) · Derivative	35,000	$21.84 Strike: $2.16	$764,400.00	Disclosure SEC source: 0001104659-18-074339 · a4.xml · derivative · entry 15 Low Philip S · CIK 0001509669 · Director · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,000 shares Expires 2027-02-02 F8 · price: This Company stock option was scheduled to vest 1/4 annually over a period of 4 years beginning on February 2, 2018. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes. F8 · derivative.exercise_date: This Company stock option was scheduled to vest 1/4 annually over a period of 4 years beginning on February 2, 2018. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes. Read SEC document
December 21, 2018 Filed Dec 21, 2018 12:47 UTC	ENDOCYTE INC ECYT · Entity 161591	Disposition to issuerStock Option (right to buy) · Derivative	52,498	$20.82 Strike: $3.18	$1,093,008.36	Disclosure SEC source: 0001104659-18-074339 · a4.xml · derivative · entry 14 Low Philip S · CIK 0001509669 · Director · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 52,498 shares Expires 2026-02-04 F7 · price: This Company stock option was scheduled to vest 1/4 annually over a period of 4 years beginning on February 4, 2017. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes. F7 · derivative.exercise_date: This Company stock option was scheduled to vest 1/4 annually over a period of 4 years beginning on February 4, 2017. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes. Read SEC document
December 21, 2018 Filed Dec 21, 2018 12:47 UTC	ENDOCYTE INC ECYT · Entity 161591	Disposition to issuerStock Option (right to buy) · Derivative	52,498	$18.90 Strike: $5.10	$992,212.20	Disclosure SEC source: 0001104659-18-074339 · a4.xml · derivative · entry 13 Low Philip S · CIK 0001509669 · Director · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 52,498 shares Expires 2025-02-04 F6 · price: This Company stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes. F6 · derivative.exercise_date: This Company stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes. Read SEC document
December 21, 2018 Filed Dec 21, 2018 12:47 UTC	ENDOCYTE INC ECYT · Entity 161591	Disposition to issuerStock Option (right to buy) · Derivative	36,000	$12.89 Strike: $11.11	$464,040.00	Disclosure SEC source: 0001104659-18-074339 · a4.xml · derivative · entry 12 Low Philip S · CIK 0001509669 · Director · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 36,000 shares Expires 2024-02-06 F6 · price: This Company stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes. F6 · derivative.exercise_date: This Company stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes. Read SEC document
December 21, 2018 Filed Dec 21, 2018 12:47 UTC	ENDOCYTE INC ECYT · Entity 161591	Disposition to issuerStock Option (right to buy) · Derivative	56,918	$14.14 Strike: $9.86	$804,820.52	Disclosure SEC source: 0001104659-18-074339 · a4.xml · derivative · entry 11 Low Philip S · CIK 0001509669 · Director · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 56,918 shares Expires 2023-02-19 F6 · price: This Company stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes. F6 · derivative.exercise_date: This Company stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes. Read SEC document
December 21, 2018 Filed Dec 21, 2018 12:47 UTC	ENDOCYTE INC ECYT · Entity 161591	Disposition to issuerStock Option (right to buy) · Derivative	59,996	$20.45 Strike: $3.55	$1,226,918.20	Disclosure SEC source: 0001104659-18-074339 · a4.xml · derivative · entry 10 Low Philip S · CIK 0001509669 · Director · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 59,996 shares Expires 2022-02-28 F6 · price: This Company stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes. F6 · derivative.exercise_date: This Company stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes. Read SEC document
December 21, 2018 Filed Dec 21, 2018 12:47 UTC	ENDOCYTE INC ECYT · Entity 161591	Disposition to issuerStock Option (right to buy) · Derivative	17,950	$12.20 Strike: $11.80	$218,990.00	Disclosure SEC source: 0001104659-18-074339 · a4.xml · derivative · entry 9 Low Philip S · CIK 0001509669 · Director · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,950 shares Expires 2021-05-26 F6 · price: This Company stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes. F6 · derivative.exercise_date: This Company stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes. Read SEC document
December 21, 2018 Filed Dec 21, 2018 12:47 UTC	ENDOCYTE INC ECYT · Entity 161591	Disposition to issuerStock Option (right to buy) · Derivative	8,560	$14.95 Strike: $9.05	$127,972.00	Disclosure SEC source: 0001104659-18-074339 · a4.xml · derivative · entry 8 Low Philip S · CIK 0001509669 · Director · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,560 shares Expires 2021-04-14 F6 · price: This Company stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes. F6 · derivative.exercise_date: This Company stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes. Read SEC document
December 21, 2018 Filed Dec 21, 2018 12:47 UTC	ENDOCYTE INC ECYT · Entity 161591	Disposition to issuerStock Option (right to buy) · Derivative	13,570	$20.18 Strike: $3.82	$273,842.60	Disclosure SEC source: 0001104659-18-074339 · a4.xml · derivative · entry 7 Low Philip S · CIK 0001509669 · Director · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,570 shares Expires 2020-02-11 F6 · price: This Company stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes. F6 · derivative.exercise_date: This Company stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes. Read SEC document
December 21, 2018 Filed Dec 21, 2018 12:47 UTC	ENDOCYTE INC ECYT · Entity 161591	Disposition to issuerCommon Stock	22,500	$24.00	$540,000.00	Disclosure SEC source: 0001104659-18-074339 · a4.xml · nonDerivative · entry 6 Low Philip S · CIK 0001509669 · Director · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F5 · price: This RSU award provided for vesting and settlement 1/4 annually over a period of 4 years beginning on February 8, 2019 in the form of one share of Company common stock for each RSU. Pursuant to the Merger Agreement, at the Effective Time, each RSU outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to $24.00, multiplied by the number of shares of Company common stock subject to such RSU, less any applicable withholding taxes. Read SEC document
December 21, 2018 Filed Dec 21, 2018 12:47 UTC	ENDOCYTE INC ECYT · Entity 161591	Disposition to issuerCommon Stock	20,000	$24.00	$480,000.00	Disclosure SEC source: 0001104659-18-074339 · a4.xml · nonDerivative · entry 5 Low Philip S · CIK 0001509669 · Director · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F4 · price: This RSU award, which originally consisted of 40,000 RSUs and of which 20,000 RSUs had vested and been settled as of immediately prior to the Effective Time, provided for vesting and settlement 1/2 annually over a period of 2 years beginning on October 4, 2018 in the form of one share of Company common stock for each RSU. Pursuant to the Merger Agreement, at the Effective Time, each RSU outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to $24.00, multiplied by the number of shares of Company common stock subject to such RSU, less any applicable withholding taxes. Read SEC document
December 21, 2018 Filed Dec 21, 2018 12:47 UTC	ENDOCYTE INC ECYT · Entity 161591	Disposition to issuerCommon Stock	13,125	$24.00	$315,000.00	Disclosure SEC source: 0001104659-18-074339 · a4.xml · nonDerivative · entry 4 Low Philip S · CIK 0001509669 · Director · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F3 · price: This RSU award, which originally consisted of 17,500 RSUs and of which 4,375 RSUs had vested and been settled as of immediately prior to the Effective Time, provided for vesting and settlement 1/4 annually over a period of 4 years beginning on February 2, 2018 in the form of one share of Company common stock for each RSU. Pursuant to the Merger Agreement, at the Effective Time, each RSU outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to $24.00, multiplied by the number of shares of Company common stock subject to such RSU, less any applicable withholding taxes. Read SEC document
December 21, 2018 Filed Dec 21, 2018 12:47 UTC	ENDOCYTE INC ECYT · Entity 161591	Disposition to issuerCommon Stock	4,375	$24.00	$105,000.00	Disclosure SEC source: 0001104659-18-074339 · a4.xml · nonDerivative · entry 3 Low Philip S · CIK 0001509669 · Director · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · price: This restricted stock unit ("RSU") award, which originally consisted of 8,750 RSUs and of which 4,375 RSUs had vested and been settled as of immediately prior to the Effective Time, provided for vesting and settlement 1/4 annually over a period of 4 years beginning on February 4, 2017 in the form of one share of Company common stock for each RSU. Pursuant to the Merger Agreement, at the Effective Time, each RSU outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to $24.00, multiplied by the number of shares of Company common stock subject to such RSU, less any applicable withholding taxes. Read SEC document
December 21, 2018 Filed Dec 21, 2018 12:47 UTC	ENDOCYTE INC ECYT · Entity 161591	Disposition to issuerCommon Stock	132,473	$24.00	$3,179,352.00	Disclosure SEC source: 0001104659-18-074339 · a4.xml · nonDerivative · entry 2 Low Philip S · CIK 0001509669 · Director · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Trust Disclosed balance after: 0 F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of October 17, 2018 (the "Merger Agreement"), by and among Endocyte, Inc. (the "Company"), Novartis AG ("Novartis") and Edinburgh Merger Corporation, a wholly owned subsidiary of Novartis ("Merger Sub"), at the effective time (the "Effective Time") of the merger of Merger Sub with and into the Company, which Effective Time occurred on December 21, 2018, each share of Company common stock was converted into the right to receive an amount in cash equal to $24.00, without interest and less any applicable withholding taxes. Read SEC document
December 21, 2018 Filed Dec 21, 2018 12:47 UTC	ENDOCYTE INC ECYT · Entity 161591	Disposition to issuerCommon Stock	349,944	$24.00	$8,398,656.00	Disclosure SEC source: 0001104659-18-074339 · a4.xml · nonDerivative · entry 1 Low Philip S · CIK 0001509669 · Director · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of October 17, 2018 (the "Merger Agreement"), by and among Endocyte, Inc. (the "Company"), Novartis AG ("Novartis") and Edinburgh Merger Corporation, a wholly owned subsidiary of Novartis ("Merger Sub"), at the effective time (the "Effective Time") of the merger of Merger Sub with and into the Company, which Effective Time occurred on December 21, 2018, each share of Company common stock was converted into the right to receive an amount in cash equal to $24.00, without interest and less any applicable withholding taxes. Read SEC document
December 17, 2018 Filed Dec 19, 2018 16:13 UTC	ENDOCYTE INC ECYT · Entity 161591	Exercise / conversionStock option (right to buy) · Derivative	2	$0.00 Strike: $3.18	$0.00	Disclosure SEC source: 0001179110-18-014132 · edgar.xml · derivative · entry 20 Low Philip S · CIK 0001509669 · Director · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,498 Underlying: Common Stock · 2 shares Expires 2026-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Shares subject to this option vest 1/4 annually over a period of four years beginning February 4, 2017. Read SEC document
December 17, 2018 Filed Dec 19, 2018 16:13 UTC	ENDOCYTE INC ECYT · Entity 161591	Exercise / conversionStock option (right to buy) · Derivative	2	$0.00 Strike: $5.10	$0.00	Disclosure SEC source: 0001179110-18-014132 · edgar.xml · derivative · entry 19 Low Philip S · CIK 0001509669 · Director · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,498 Underlying: Common Stock · 2 shares Expires 2025-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option is fully vested and immediately exercisable. Read SEC document
December 17, 2018 Filed Dec 19, 2018 16:13 UTC	ENDOCYTE INC ECYT · Entity 161591	Exercise / conversionStock option (right to buy) · Derivative	9,000	$0.00 Strike: $11.11	$0.00	Disclosure SEC source: 0001179110-18-014132 · edgar.xml · derivative · entry 18 Low Philip S · CIK 0001509669 · Director · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,000 Underlying: Common Stock · 9,000 shares Expires 2024-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option is fully vested and immediately exercisable. Read SEC document
December 17, 2018 Filed Dec 19, 2018 16:13 UTC	ENDOCYTE INC ECYT · Entity 161591	Exercise / conversionStock option (right to buy) · Derivative	13,082	$0.00 Strike: $9.86	$0.00	Disclosure SEC source: 0001179110-18-014132 · edgar.xml · derivative · entry 17 Low Philip S · CIK 0001509669 · Director · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,918 Underlying: Common Stock · 13,082 shares Expires 2023-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option is fully vested and immediately exercisable. Read SEC document
December 17, 2018 Filed Dec 19, 2018 16:13 UTC	ENDOCYTE INC ECYT · Entity 161591	Exercise / conversionStock option (right to buy) · Derivative	20,004	$0.00 Strike: $3.55	$0.00	Disclosure SEC source: 0001179110-18-014132 · edgar.xml · derivative · entry 16 Low Philip S · CIK 0001509669 · Director · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,996 Underlying: Common Stock · 20,004 shares Expires 2022-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option is fully vested and immediately exercisable. Read SEC document
December 17, 2018 Filed Dec 19, 2018 16:13 UTC	ENDOCYTE INC ECYT · Entity 161591	Exercise / conversionStock option (right to buy) · Derivative	2,050	$0.00 Strike: $11.80	$0.00	Disclosure SEC source: 0001179110-18-014132 · edgar.xml · derivative · entry 15 Low Philip S · CIK 0001509669 · Director · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,950 Underlying: Common Stock · 2,050 shares Expires 2021-05-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option is fully vested and immediately exercisable. Read SEC document
December 17, 2018 Filed Dec 19, 2018 16:13 UTC	ENDOCYTE INC ECYT · Entity 161591	Exercise / conversionStock Option (right to buy) · Derivative	21,440	$0.00 Strike: $9.05	$0.00	Disclosure SEC source: 0001179110-18-014132 · edgar.xml · derivative · entry 14 Low Philip S · CIK 0001509669 · Director · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,560 Underlying: Common Stock · 21,440 shares Expires 2021-04-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option is fully vested and immediately exercisable. Read SEC document
December 17, 2018 Filed Dec 19, 2018 16:13 UTC	ENDOCYTE INC ECYT · Entity 161591	Exercise / conversionStock Option (right to buy) · Derivative	51,875	$0.00 Strike: $3.82	$0.00	Disclosure SEC source: 0001179110-18-014132 · edgar.xml · derivative · entry 13 Low Philip S · CIK 0001509669 · Director · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,570 Underlying: Common Stock · 51,875 shares Expires 2020-02-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option is fully vested and immediately exercisable. Read SEC document
December 17, 2018 Filed Dec 19, 2018 16:13 UTC	ENDOCYTE INC ECYT · Entity 161591	Exercise / conversionStock Option (right to buy) · Derivative	22,759	$0.00 Strike: $2.54	$0.00	Disclosure SEC source: 0001179110-18-014132 · edgar.xml · derivative · entry 12 Low Philip S · CIK 0001509669 · Director · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,759 shares Expires 2019-03-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option is fully vested and immediately exercisable. Read SEC document
December 17, 2018 Filed Dec 19, 2018 16:13 UTC	ENDOCYTE INC ECYT · Entity 161591	Exercise / conversionCommon Stock	2	$3.18	$6.36	Disclosure SEC source: 0001179110-18-014132 · edgar.xml · nonDerivative · entry 11 Low Philip S · CIK 0001509669 · Director · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 409,944 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
December 17, 2018 Filed Dec 19, 2018 16:13 UTC	ENDOCYTE INC ECYT · Entity 161591	Exercise / conversionCommon Stock	2	$5.10	$10.20	Disclosure SEC source: 0001179110-18-014132 · edgar.xml · nonDerivative · entry 10 Low Philip S · CIK 0001509669 · Director · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 409,942 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
December 17, 2018 Filed Dec 19, 2018 16:13 UTC	ENDOCYTE INC ECYT · Entity 161591	Exercise / conversionCommon Stock	9,000	$11.11	$99,990.00	Disclosure SEC source: 0001179110-18-014132 · edgar.xml · nonDerivative · entry 9 Low Philip S · CIK 0001509669 · Director · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 409,940 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
December 17, 2018 Filed Dec 19, 2018 16:13 UTC	ENDOCYTE INC ECYT · Entity 161591	Exercise / conversionCommon Stock	13,082	$9.86	$128,988.52	Disclosure SEC source: 0001179110-18-014132 · edgar.xml · nonDerivative · entry 8 Low Philip S · CIK 0001509669 · Director · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,940 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
December 17, 2018 Filed Dec 19, 2018 16:13 UTC	ENDOCYTE INC ECYT · Entity 161591	Exercise / conversionCommon Stock	20,004	$3.55	$71,014.20	Disclosure SEC source: 0001179110-18-014132 · edgar.xml · nonDerivative · entry 7 Low Philip S · CIK 0001509669 · Director · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 387,858 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
December 17, 2018 Filed Dec 19, 2018 16:13 UTC	ENDOCYTE INC ECYT · Entity 161591	Exercise / conversionCommon Stock	2,050	$11.80	$24,190.00	Disclosure SEC source: 0001179110-18-014132 · edgar.xml · nonDerivative · entry 6 Low Philip S · CIK 0001509669 · Director · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 367,854 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
December 17, 2018 Filed Dec 19, 2018 16:13 UTC	ENDOCYTE INC ECYT · Entity 161591	Exercise / conversionCommon Stock	21,440	$9.05	$194,032.00	Disclosure SEC source: 0001179110-18-014132 · edgar.xml · nonDerivative · entry 5 Low Philip S · CIK 0001509669 · Director · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 365,804 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
December 17, 2018 Filed Dec 19, 2018 16:13 UTC	ENDOCYTE INC ECYT · Entity 161591	Exercise / conversionCommon Stock	51,875	$3.82	$198,162.50	Disclosure SEC source: 0001179110-18-014132 · edgar.xml · nonDerivative · entry 4 Low Philip S · CIK 0001509669 · Director · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 344,364 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
December 17, 2018 Filed Dec 19, 2018 16:13 UTC	ENDOCYTE INC ECYT · Entity 161591	Exercise / conversionCommon Stock	22,759	$2.54	$57,807.86	Disclosure SEC source: 0001179110-18-014132 · edgar.xml · nonDerivative · entry 3 Low Philip S · CIK 0001509669 · Director · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 292,489 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · balance_after: Includes 526 shares acquired under the 2010 Endocyte, Inc. Employee Stock Purchase Plan on December 14, 2018. Read SEC document
December 12, 2018 Filed Dec 19, 2018 16:13 UTC	ENDOCYTE INC ECYT · Entity 161591	GiftCommon Stock	52,346	$0.00	$0.00	Disclosure SEC source: 0001179110-18-014132 · edgar.xml · nonDerivative · entry 2 Low Philip S · CIK 0001509669 · Director · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 269,204 F2 · shares: Represents a gift of 52,346 shares to a non-profit organization. Read SEC document
December 12, 2018 Filed Dec 19, 2018 16:13 UTC	ENDOCYTE INC ECYT · Entity 161591	GiftCommon Stock	52,512	$0.00	$0.00	Disclosure SEC source: 0001179110-18-014132 · edgar.xml · nonDerivative · entry 1 Low Philip S · CIK 0001509669 · Director · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Trust Disclosed balance after: 132,473 F1 · shares: Represents gifts of 52,512 shares by Spouse Trust to non-profit organizations. Read SEC document
October 05, 2018 Filed Oct 9, 2018 14:14 UTC	ENDOCYTE INC ECYT · Entity 161591	SaleCommon Stock	5,928	$15.56	$92,237.90	Disclosure SEC source: 0001179110-18-012085 · edgar.xml · nonDerivative · entry 2 Low Philip S · CIK 0001509669 · Director · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 319,817 F1 · shares: Represents the sale of 5,928 shares in multiple transactions ranging in price from $15.1400 to $15.9200, resulting in a weighted-average price of $15.5597. The 5,928 shares were sold to cover taxes, commissions and fees associated with the October 4, 2018 settlement of 20,000 restricted stock units in the form of Company common stock on a one-for-one basis. The shares were sold pursuant to a written plan as specified in Rule 10b5-1(c) of the Securities Exchange Act of 1934. Read SEC document
October 05, 2018 Filed Oct 16, 2018 16:18 UTC Amendment	ENDOCYTE INC ECYT · Entity 161591	SaleCommon Stock	5,928	$15.56	$92,237.90	Disclosure SEC source: 0001179110-18-012206 · edgar.xml · nonDerivative · entry 2 Low Philip S · CIK 0001509669 · Director · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 321,550 F1 · shares: Represents the sale of 5,928 shares in multiple transactions ranging in price from $15.1400 to $15.9200, resulting in a weighted-average price of $15.5597. The 5,928 shares were sold to cover taxes, commissions and fees associated with the October 4, 2018 settlement of 20,000 restricted stock units in the form of Company common stock on a one-for-one basis. The shares were sold pursuant to a written plan as specified in Rule 10b5-1(c) of the Securities Exchange Act of 1934. F2 · balance_after: Includes 1,733 shares acquired under the Endocyte, Inc. 2010 Employee Stock Purchase Plan on June 15, 2018 that were inadvertently omitted from the amount of securities beneficially owned by the reporting person as reported on the Form 4 filed by the reporting person on October 9, 2018. Read SEC document
September 07, 2018 Filed Oct 9, 2018 14:14 UTC	ENDOCYTE INC ECYT · Entity 161591	GiftCommon Stock	294	$0.00	$0.00	Disclosure SEC source: 0001179110-18-012085 · edgar.xml · nonDerivative · entry 1 Low Philip S · CIK 0001509669 · Director · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 325,745 Read SEC document
September 07, 2018 Filed Oct 16, 2018 16:18 UTC Amendment	ENDOCYTE INC ECYT · Entity 161591	GiftCommon Stock	294	$0.00	$0.00	Disclosure SEC source: 0001179110-18-012206 · edgar.xml · nonDerivative · entry 1 Low Philip S · CIK 0001509669 · Director · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 327,478 F2 · balance_after: Includes 1,733 shares acquired under the Endocyte, Inc. 2010 Employee Stock Purchase Plan on June 15, 2018 that were inadvertently omitted from the amount of securities beneficially owned by the reporting person as reported on the Form 4 filed by the reporting person on October 9, 2018. Read SEC document
February 08, 2018 Filed Feb 8, 2018 16:45 UTC	ENDOCYTE INC ECYT · Entity 161591	GrantStock option (right to buy) · Derivative	45,000	$0.00 Strike: $3.01	$0.00	Disclosure SEC source: 0001179110-18-001812 · edgar.xml · derivative · entry 3 Low Philip S · CIK 0001509669 · Director · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common stock · 45,000 shares Expires 2028-02-08 F2 · derivative.exercise_date: Stock subject to the option will vest 1/4 annually over a 4 year period beginning 2/8/19. Read SEC document
February 08, 2018 Filed Feb 8, 2018 16:45 UTC	ENDOCYTE INC ECYT · Entity 161591	GrantCommon Stock	22,500	$0.00	$0.00	Disclosure SEC source: 0001179110-18-001812 · edgar.xml · nonDerivative · entry 1 Low Philip S · CIK 0001509669 · Director · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 326,039 F1 · shares: Represents restricted stock units that will vest 1/4 annually over a 4 year period beginning 2/8/19, in the form of one share of common stock for each restricted stock unit. Read SEC document
December 28, 2017 Filed Jan 2, 2018 15:39 UTC	ENDOCYTE INC ECYT · Entity 161591	Exercise / conversionStock Option (right to buy) · Derivative	65,445	$0.00 Strike: $3.06	$0.00	Disclosure SEC source: 0001179110-18-000069 · edgar.xml · derivative · entry 4 Low Philip S · CIK 0001509669 · Director · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 65,445 shares Expires 2018-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option is fully vested and immediately exercisable. Read SEC document
December 28, 2017 Filed Jan 2, 2018 15:39 UTC	ENDOCYTE INC ECYT · Entity 161591	SaleCommon Stock	50,511	$4.41	$222,824.23	Disclosure SEC source: 0001179110-18-000069 · edgar.xml · nonDerivative · entry 2 Low Philip S · CIK 0001509669 · Director · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 303,539 F1 · shares: Represents the sale of 50,511 shares in multiple transactions, ranging in price from $4.2700 to $4.5100 per share, resulting in a weighted average sale price per share of $4.4114. These shares were sold to cover the option exercise cost, taxes and fees in connection with the reporting person's exercise of stock options on December 28, 2017 as reported herein. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range. Read SEC document
December 28, 2017 Filed Jan 2, 2018 15:39 UTC	ENDOCYTE INC ECYT · Entity 161591	Exercise / conversionCommon Stock	65,445	$3.06	$200,261.70	Disclosure SEC source: 0001179110-18-000069 · edgar.xml · nonDerivative · entry 1 Low Philip S · CIK 0001509669 · Director · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 354,050 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
December 22, 2017 Filed Jan 2, 2018 15:39 UTC	ENDOCYTE INC ECYT · Entity 161591	GiftCommon Stock	8,333	$0.00	$0.00	Disclosure SEC source: 0001179110-18-000069 · edgar.xml · nonDerivative · entry 3 Low Philip S · CIK 0001509669 · Director · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse trust Disclosed balance after: 184,985 F2 · shares: Represents a gift of 8,333 shares by Spouse Trust to a non-profit organization. Read SEC document
November 13, 2017 Filed Nov 14, 2017 15:26 UTC	ENDOCYTE INC ECYT · Entity 161591	PurchaseCommon Stock	5,600	$4.84	$27,104.00	Disclosure SEC source: 0001179110-17-014106 · edgar.xml · nonDerivative · entry 2 Low Philip S · CIK 0001509669 · Director · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 288,605 F2 · shares: Represents the purchase of 5,600 shares in multiple transactions, ranging in price from $4.825 to $4.850 per share, resulting in a weighted average purchase price per share of $4.840. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price within the range. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.